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Pathophysiology of ANCA-associated vasculitides: Are ANCA
really pathogenic? The strong association of antineutrophil cy-
toplasmic autoantibodies (ANCA) with certain forms of small
vessel vasculitis suggests a pathogenic role of these autoan-
tibodies in the disease process. In vitro, ANCA can activate
neutrophils and monocytes to produce reactive oxygen inter-
mediates, to release lysosomal enzymes, and to secrete proin-
flammatory cytokines. More recently, it was demonstrated that
antimyeloperoxidase ANCA can induce systemic vasculitis and
glomerulonephritis in mice. Taken together, these data provide
convincing evidence that ANCA are indeed pathogenic.
Within the group of small vessel vasculitides,
Wegener’s granulomatosis, microscopic polyangiitis,
Churg-Strauss syndrome, and the renal limited forms
of these disease (i.e., idiopathic necrotizing crescen-
tic glomerulonephritis) are strongly associated with an-
tineutrophil cytoplasmic autoantibodies (ANCAs) [1].
ANCAs are a group of autoantibodies directed against
enzymes contained in neutrophil granules and lysosomes
of monocytes. The main antigenic targets of ANCAs are
proteinase 3 (PR3), a 29 kD serine protease, and
myeloperoxidase (MPO), a 140 kD enzyme involved
in the generation of reactive oxygen species. To date,
many clinical studies have confirmed that PR3-ANCA
and MPO-ANCA are highly specific for Wegener’s gran-
ulomatosis and microscopic polyangiitis, respectively [1].
Since the discovery of ANCAs in the early 1980s, the
detection of these autoantibodies has proven to be an im-
portant diagnostic marker and, currently, is routine prac-
tice in many laboratories around the world. Also, given
the strong association of ANCA with these diseases, hy-
potheses have been raised about the possible pathogenic
role of ANCAs in the disease process.
Here, we will briefly summarize the evidence obtained
from in vitro and in vivo studies that ANCAs are a ma-
1Participant and speaker.
Key words: ANCA, vasculitis, microscopic polyangiitis.
C© 2004 by the International Society of Nephrology
jor player in the pathophysiology of ANCA-associated
vasculitides.
IN VITRO EVIDENCE THAT ANCA
ARE PATHOGENIC
It is generally accepted now that ANCAs are capable
of activating the cells that are the source of the ANCA
antigens (i.e., neutrophils and monocytes [2]). In this re-
spect, the best studied effects of ANCA on these cells are
induction of the respiratory burst and the extracellular
release of lysosomal enzymes, including the ANCA anti-
gens themselves [2]. Coincubation of ANCA-activated
neutrophils and endothelial cells results in endothelial
cell lysis, suggesting that these effector pathways can be
responsible for the vessel wall injury observed in vivo
[3, 4]. Moreover, ANCAs can stimulate monocytes to
produce proinflammatory cytokines such as interleukin
(IL)-1b , tumor necrosis factor-a (TNF-a), IL-6, IL-8,
and monocyte chemoattractant protein-1 (MCP-1) [5–7].
Through recruitment and activation of leukocytes, these
cytokines may contribute to the amplification and prop-
agation of the inflammatory response associated with
necrotizing vasculitis.
Although the exact mechanisms involved in ANCA-
induced neutrophil activation are not completely un-
derstood, most studies have shown a requirement for
neutrophil priming with proinflammatory stimuli, in par-
ticular TNF-a [2]. Neutrophil priming refers to the
process where the response of the cell to an activating
stimulus is enhanced by prior exposure to low nonactivat-
ing concentrations of the same or another stimulus. In the
case of TNF-a, priming induces up-regulation of adhesion
molecule expression and facilitates the reduced form of
nicotinamide adenine dinucleotide phosphate (NADPH)
oxidase complex formation through the translocation of
cytochrome b558 to the cell surface [8, 9]. Importantly,
it also results in expression of the ANCA antigens on
the cell surface making them accessible for interaction
with ANCA [10, 11]. Simultaneous engagement of the
Fab portion of ANCA with ANCA antigens on the cell
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surface and interaction of the Fc part of the antibody
with Fc receptors is generally thought to be a prerequi-
site for ANCA-induced neutrophil activation [1, 12, 13].
In some studies, however, F(ab)2 fragments of the ANCA
antibodies have been found to activate neutrophils, sug-
gesting that Fc receptor independent pathways are in-
volved in ANCA-induced neutrophil activation as well
[14]. The observation that ANCA-induced neutrophil ac-
tivation requires prior priming of the neutrophil corre-
lates well with the clinical observation that, in patients
suffering from systemic vasculitis, exacerbations are of-
ten preceded by infections.
Investigations into the signal-transduction pathways
activated in ANCA-induced neutrophil stimulation have
demonstrated the involvement of p38 mitogen-activated
protein kinases (MAPK), extracellular signal-regulated
kinases (ERK), as well as phosphatidylinositol 3 (PI3)
kinase signaling systems [15–17]. However, this area of
ANCA research is still in its infancy and much remains
to be discovered. In this respect, Yang et al [18] recently
made use of the microarray technology to study differ-
ential gene expression in neutrophils activated by whole
ANCA IgG or ANCA F(ab)2 fragments. They observed
that expression of some genes was unique to activation
by whole ANCA IgG, whereas other genes were prefer-
entially induced by F(ab)2 fragments of the antibodies.
In the future, this approach, together with detailed bio-
chemical and molecular studies, may help in elucidating
the mechanisms of ANCA-induced neutrophil activation
and provide more insight into the underlying signaling
pathways.
IN VIVO EVIDENCE THAT ANCA ARE
PATHOGENIC
Although in vitro experiments as described above sup-
port the contention that ANCA are pathogenic, animal
models are required to prove causality. The development
of an animal model for ANCA-associated vasculitis has,
however, proven to be a difficult task. Using various ex-
perimental approaches, several animal models have been
proposed but all of these have important limitations.
For example, MPO-ANCA can be detected in mercury
chloride–treated rats and in autoimmune prone mouse
strains such as MRL-lpr/lpr mice and SCG/Kj mice [19–
21]. However, in these animals, various other autoanti-
bodies are induced due to polyclonal B-cell activation,
which complicates evaluation of the pathogenicity of the
MPO-ANCAs.
Active immunization of rats with human MPO induces
antibodies to human MPO that crossreact with rat MPO.
In these rats, subsequent renal perfusion or systemic ad-
ministration of human neutrophil lysosomal extracts in-
duces crescentic glomerulonephritis or pulmonary and
intestinal vasculitis, respectively [22, 23]. Also, crescentic
glomerulonephritis develops in human MPO-immunized
rats treated with doses of anti-glomerular basement
membrane (GBM) antibodies that in control immunized
rats lead to mild anti-GBM disease only [24]. These stud-
ies indicate that MPO-ANCA can render mild glomerular
injury into clinically severe disease but do not prove that
ANCAs are an independent cause of disease. Moreover,
these models are hampered by the use of heterologous
MPO and neutrophil extracts and in that sense are not
autoimmune models.
In preliminary studies [abstract; Smyth et al, J Am Soc
Nephrol 13s:170S, 2002], it was recently found that Wis-
tar Kyoto (WKY) rats also develop circulating anti-rat
MPO antibodies upon immunization with human MPO.
Interestingly, these rats developed proteinuria and hema-
turia and, 8 weeks after immunization, showed segmen-
tal inflammation of glomeruli, deposits of fibrin with
and without crescents, tubular red cell casts, and tubu-
lointerstitial inflammation. In the lungs, signs of alveo-
lar hemorrhage, perivascular cuffing by leukocytes and
fibrin deposits in vessel walls were found. The paucity
of immune complexes observed on immunohistochemi-
cal evaluation closely resembles the human disease. This
promising study emphasizes the importance of the back-
ground rat strain and timing in the development of mod-
els of ANCA-associated vasculitis.
In a recent study, Xiao et al [25] provided direct
and convincing evidence that MPO-ANCA can cause
pauci-immune glomerulonephritis and vasculitis in mice.
The strategy used in this study is depicted in Figure 1
and is based on immunization of MPO-deficient mice
to circumvent tolerance to MPO that would normally
occur in MPO-expressing mice. Indeed, it was shown
that when MPO −/− mice were immunized with murine
MPO, circulating antimurine MPO antibodies devel-
oped. Adoptive transfer of anti-MPO splenocytes into
immune-deficient recombinase activating gene-deficient
mice (Rag2 −/−) that lack functioning T and B cells re-
sulted in circulating anti-MPO-ANCA and the develop-
ment of crescentic glomerulonephritis and systemic vas-
culitis. In contrast, Rag2 −/− mice receiving splenocytes
from bovine serum albumin (BSA)-immunized MPO−/−
mice developed only mild glomerulonephritis without
necrosis or crescents.
To test the pathogenic potential of the antibodies
alone, a second series of experiments was performed in
which purified IgG from murine MPO or BSA immu-
nized MPO −/− mice was intravenously injected into
Rag2 −/− mice or wild-type mice. These studies showed
that passive transfer of anti-MPO IgG induces a pauci-
immune, focal necrotizing crescentic glomerulonephri-
tis and systemic vasculitis mimicking the human dis-
ease and provide direct evidence that MPO-ANCA are
pathogenic.
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Fig. 1. Strategy for the development of
a mouse model of anti-myeloperoxidase
(MPO)-associated glomerulonephritis/
vasculitis. 1, MPOdeficient mice (MPO
−/−) are immunized with murine MPO
(muMPO) or bovine serum albumin (BSA).
2, Splenocytes and IgG are obtained from
immunized MPO −/− mice. 3, Adoptive
transfer of BSA+ splenocytes into Rag2
−/− or passive transfer of BSA+ IgG into
Rag2 −/− or wild-type mice induces no
disease. 4, Adoptive transfer of muMPO+
splenocytes into Rag2 −/− or passive transfer
of muMPO+ IgG into Rag2 −/− or wild-type
mice induces vascultitis and necrotizing
crescentic glomerulonephritis. Images
represent glomerular lesions as observed
6 days after passive transfer into wild-type
mice of anti-BSA IgG and anti-MPO IgG,
respectively [periodic acid-Schiff (PAS)
staining, ×400).
CONCLUSION
Evidence derived from in vitro studies in conjunc-
tion with the in vivo observation that MPO-ANCAs in-
duce systemic vasculitis in mice implies that the associa-
tion in patients between MPO-ANCA and pauci-immune
glomerulonephritis and vasculitis is due to causation. Im-
portantly, the mouse model will be a powerful tool for
the study of pathogenic processes involved in ANCA-
induced vasculitis, to identify new targets for treatment,
and to test new experimental therapies. It will be inter-
esting to see whether, using a similar approach, an animal
model for PR3-ANCA-induced vasculitis can be devel-
oped. This would not only increase the evidence for a
pathogenic role of ANCAs but could also give more in-
sight into the possible pathophysiologic differences be-
tween MPO- and PR3-ANCA associated disease as has
been proposed by some investigators [26].
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